Puma Biotechnology Presents Positive PB272 Clinical Data at ASCO 2012 … – EON: Enhanced Online News (press release)
By Dr. Matthew Watson
Puma Biotechnology Presents Positive PB272 Clinical Data at ASCO 2012 ... EON: Enhanced Online News (press release) LOS ANGELES--(EON: Enhanced Online News)--Puma Biotechnology, Inc. (OTCBB: PBYI), a development stage biopharmaceutical company, announced that results from an ongoing Phase I clinical trial of its lead drug candidate PB272 (neratinib) given in ... |
Uncategorized
Comments Off on Puma Biotechnology Presents Positive PB272 Clinical Data at ASCO 2012 … – EON: Enhanced Online News (press release) |
June 8th, 2013
This author published 5552 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research